Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

12.63 -0.30 (-2.35%)
Streaming Delayed Price Updated: 12:51 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 298,356
Open 12.88
Bid (Size) 12.61 (800)
Ask (Size) 12.63 (400)
Prev. Close 12.93
Today's Range 12.63 - 13.12
52wk Range 10.70 - 34.13
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
From Novocure
Via Business Wire
News headline image
NovoCure (NVCR) Q3 2025 Earnings Call Transcript ↗
NovoCure (NVCR) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade

Performance

YTD
-57.9%
-57.9%
1 Month
+12.0%
+12.0%
3 Month
-0.4%
-0.4%
6 Month
-27.6%
-27.6%
1 Year
-60.2%
-60.2%

More News

Read More
News headline image
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
From Novocure
Via Business Wire
News headline image
2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon ↗
Via The Motley Fool
News headline image
Earnings Scheduled For October 30, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For July 24, 2025 ↗
Via Benzinga
News headline image
NovoCure Earnings Preview ↗
Via Benzinga
News headline image
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
From Novocure
Via Business Wire
News headline image
Novocure (NASDAQ:NVCR) Q3 2025 Earnings: Revenue Beat and Narrower Loss Drive Shares Higher ↗
Via Chartmill
News headline image
Novocure Reports Third Quarter 2025 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
From Novocure
Via Business Wire
News headline image
Novocure to Report Third Quarter 2025 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
From Novocure
Via Business Wire
News headline image
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
From Novocure
Via Business Wire
News headline image
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗
Via The Motley Fool
News headline image
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire
News headline image
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
From Novocure
Via Business Wire
News headline image
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
News headline image
Top 3 Health Care Stocks That May Explode In July ↗
Via Benzinga
News headline image
NovoCure Q2 Revenue Jumps 6 Percent ↗
Via The Motley Fool
Topics World Trade
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Novocure: Steady Ahead of Key Milestones ↗
Via The Motley Fool
News headline image
Novocure Reports Second Quarter 2025 Financial Results
From Novocure
Via Business Wire
News headline image
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday ↗
Via Benzinga
News headline image
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
From Novocure
Via Business Wire

Frequently Asked Questions

Is NovoCure Limited - Ordinary Shares publicly traded?
Yes, NovoCure Limited - Ordinary Shares is publicly traded.
What exchange does NovoCure Limited - Ordinary Shares trade on?
NovoCure Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NovoCure Limited - Ordinary Shares?
The ticker symbol for NovoCure Limited - Ordinary Shares is NVCR on the Nasdaq Stock Market
What is the current price of NovoCure Limited - Ordinary Shares?
The current price of NovoCure Limited - Ordinary Shares is 12.63
When was NovoCure Limited - Ordinary Shares last traded?
The last trade of NovoCure Limited - Ordinary Shares was at 12/17/25 12:51 PM ET
What is the market capitalization of NovoCure Limited - Ordinary Shares?
The market capitalization of NovoCure Limited - Ordinary Shares is 1.31B
How many shares of NovoCure Limited - Ordinary Shares are outstanding?
NovoCure Limited - Ordinary Shares has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.